Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine
- 2 June 2016
- journal article
- review article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 16 (4) , 241-253
Abstract
Statins, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers (CCBs) have markedly changed the clinical progression of patients with coronary artery disease (CAD). The goal of this paper is to review the rationale and evidence for combining these three drug classes in hypertensive patients with hypercholesterolemia or CAD. Data sources include a literature search for publications on the use of a statin combined with various antihypertensive drugs in patients with hypertension and hypercholesterolemia or stable CAD. Hypercholesterolemia and hypertension constitute major physiological risk factors of ischemic heart disease. Current guidelines recommend a global approach to risk management, using agents that address as many risk factors as possible. Dual combination therapies are an important component of guideline-recommended therapy in hypertension. Our review of the literature indicates that triple therapy with a statin, ACE inhibitor, and CCB is associated with a significant reduction in major cardiovascular events. For example, a post hoc analysis in 1056 patients with stable CAD participating in the EUROPA trial indicated that the addition of perindopril to a CCB and a lipid-lowering agent was associated with a 46 % reduction in the composite of cardiovascular death, myocardial infarction, and resuscitated cardiac arrest (p = 0.023). In addition, single pill formulations are known to result in better adherence to the treatment. Single-pill formulations that combine a statin, an ACE inhibitor, and a CCB appear to offer an effective approach to the management of global cardiovascular risk.Keywords
This publication has 60 references indexed in Scilit:
- Hypertension Management: Rationale for Triple Therapy Based on Mechanisms of ActionCardiovascular Therapeutics, 2013
- The Efficacy and Tolerability of ‘Polypills’: Meta-Analysis of Randomised Controlled TrialsPLOS ONE, 2012
- Hypertension Control and Cardiometabolic Risk: A Regional PerspectiveCardiology Research and Practice, 2012
- Better compliance to antihypertensive medications reduces cardiovascular riskJournal Of Hypertension, 2011
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Progression of Cardiovascular Damage: The Role of Renin–Angiotensin System BlockadeThe American Journal of Cardiology, 2010
- Amlodipine/AtorvastatinDrugs, 2010
- Insight into the Mode of Action of ACE Inhibition in Coronary Artery DiseaseDrugs, 2009
- A meta-analysis of the association between adherence to drug therapy and mortalityBMJ, 2006
- Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart diseaseJournal of Human Hypertension, 2004